Prothrombin complex concentrate (human) - Biologic Drug Details

Summary for prothrombin complex concentrate (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for prothrombin complex concentrate (human)

Recent Clinical Trials for prothrombin complex concentrate (human)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Imam Abdulrahman Bin Faisal University	PHASE3
Johns Hopkins Aramco Healthcare	PHASE3
Second Affiliated Hospital, School of Medicine, Zhejiang University	N/A

See all prothrombin complex concentrate (human) clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for prothrombin complex concentrate (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for prothrombin complex concentrate (human) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Csl Behring Gmbh	KCENTRA	prothrombin complex concentrate (human)	For Injection	125421		2027-12-18	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for prothrombin complex concentrate (human) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for prothrombin complex concentrate (human)

Country	Patent Number	Estimated Expiration
Spain	2788075
Poland	2125004
Australia	2007338385
Denmark	2125004
Japan	5331704

Market Dynamics and Financial Trajectory for Human Prothrombin Complex Concentrate (PCC)

Last updated: March 11, 2026

What Drives Market Demand for Human Prothrombin Complex Concentrate?

Prothrombin complex concentrate (PCC) is used to treat certain coagulation disorders, primarily vitamin K antagonist-related bleeding, warfarin reversal, and deficiencies in clotting factors. The global market's growth hinges on multiple factors:

• Increment in anticoagulant use: The rising prevalence of atrial fibrillation, venous thromboembolism, and mechanical heart valve replacements drives increased use of anticoagulants, subsequently elevating demand for reversal agents such as PCC.
• Aging population: Older adults are more prone to thrombotic events requiring anticoagulation, amplifying need for PCC.
• Shift from fresh frozen plasma (FFP): PCC offers faster, more reliable reversal of anticoagulation, replacing FFP in many cases.
• Advances in manufacturing: Improved plasma-derived techniques and recombinant products enhance safety and efficacy profiles, fueling adoption.
• Regulatory approvals: Expanded indications and approvals in various regions bolster market access and uptake.

What Are the Key Market Players?

Major pharmaceutical companies manufacturing human PCC include:

Company	Product Name	Market Share	Presence	Notes
CSL Behring	Beriplex P/N	Largest	Global	Approved in multiple regions; high safety profile
Grifols	Octaplex	Significant	Europe, North America	Focused on Europe; expanding in US
Sanquin	Prothromplex	Niche	Netherlands	Mainly regional presence
Others	Various	Emerging	Asia, Latin America	Market growth attracts new entrants

How Do Regulatory Frameworks Impact the Market?

• United States: The FDA approved Beriplex for urgent warfarin reversal in 2010, with continued indications expansion. FDA requires rigorous plasma safety standards, influencing manufacturing costs.
• Europe: EMA approvals for PCC use in vitamin K antagonist reversal facilitate distribution. Different countries may have varying approval statuses, impacting regional market size.
• Asia-Pacific: Regulatory pathways are evolving; approval processes influence market entry timing and costs.

What Are Revenue and Growth Trends?

• Global Market Values: Estimated at roughly $1.2 billion in 2022 (MarketWatch). Expected CAGR of 7-9% over next five years due to rising anticoagulant use.
• Regional revenues: North America accounts for over 50% of sales; Europe 30%; Asia-Pacific rapidly growing due to demographic trends and expanding healthcare infrastructure.
• Market segmentation: Human PCC dominates the coagulation reversal segment, with an emerging trend towards recombinant alternatives under development.

How Do Competitive Forces Shape the Financial Outlook?

• Pricing strategies: High manufacturing costs influence premium pricing; patent protections and regulatory exclusivities limit generic competition.
• Product differentiation: Safety profile and ease of use serve as differentiators.
• Pipeline products: Recombinant PCC and other novel agents aim to challenge plasma-derived PCCs, potentially impacting future revenue streams.
• Reimbursement policies: Insurance coverage and hospital formularies significantly affect adoption rates.

What Are Future Revenue Drivers and Challenges?

Drivers:

• Increasing anticoagulant prescriptions.
• Aging demographic with a higher need for coagulation management.
• Expanding indications, such as trauma and surgical bleeding.

Challenges:

• Development of recombinant alternatives which could reduce reliance on plasma-derived PCCs.
• Stringent plasma donation and processing regulations.
• Supply chain complexities, including plasma shortages.
• Competition from emerging reversal agents like andexanet alfa, which target specific anticoagulants and may replace PCC in certain settings.

What Is the Financial Trajectory Outlook?

• Revenue Growth: Expected steady increase, averaging 8% annually over the next five years, driven by regional expansions and increased clinical use.
• Profit Margins: Historically high due to the specialized nature; margins could tighten with new entrants and biosimilars.
• Investment opportunities: Companies investing early in pipeline developments or expanding manufacturing capacity could realize significant gains, especially in emerging markets.

Key Takeaways

• Demand for human PCC is rising due to increasing anticoagulant use and demographic aging.
• Market growth is tempered by regulatory hurdles and the emergence of competing technologies.
• North America dominates current revenues but Asia-Pacific offers significant growth potential.
• Revenue growth will be sustained by expanded indications and regional market penetrations, but patent expirations and pipeline competition pose risks.
• The market remains attractive for established players with strong regulatory and manufacturing capabilities, alongside opportunities for new entrants with innovative products.

FAQs

1. What factors most influence the growth of human PCC?
The aging population, rising anticoagulant prescriptions, and advantages over traditional plasma products are primary drivers.

2. How does the emergence of recombinant PCC impact the market?
Recombinant PCC could reduce reliance on plasma-derived products, potentially lowering costs and improving safety, impacting market share.

3. What are prospects for new entrants in the PCC market?
While high regulatory and manufacturing barriers exist, innovative recombinant products and regional expansions offer opportunities for newcomers.

4. How do reimbursement policies affect PCC market expansion?
Reimbursement influences hospital adoption. Favorable policies lead to broader use, while restrictive reimbursement hampers growth.

5. What regulatory hurdles could slow market growth?
Stringent plasma safety standards, approval delays, and regional regulatory disparities can delay product launches and expansion.

---

References

[1] MarketWatch. (2022). Prothrombin complex concentrate (PCC) market size, share, trends, and forecast.
[2] FDA. (2010). Approval documentation for Beriplex P/N.
[3] EMA. (2015). Guidelines for coagulation factor concentrates.
[4] GlobalData. (2022). Coagulation factor market analysis, 2022-2027.